MAXIMISE (Managing AXlaI Manifestations in Psorlatic Arthritis with SEcukinumab), a randomized, doubled-blind, placebo-controlled, multi center, 52-week study to assess the efficacy ans safety of secukinumab 150 mg or 300 mg s.c. in patients with active psoriatic arthritis and axial skeleton involvement who have inadequate response to non-steroidal anti-infiammatory drugs (NSAIDs)

Starting date
September 28, 2016
Duration (months)
60
Departments
Medicine
Managers or local contacts
Idolazzi Luca , Rossini Maurizio

Project participants

Luca Idolazzi
Temporary Assistant Professor
Maurizio Rossini
Full Professor
Research areas involved in the project
Rheumatology  (DM)
Rheumatology  (DNBM)

Activities

Research facilities